Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)

NCT01138397 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

129

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: Influenza virus vaccine (split virion, inactivated)
BIOLOGICAL: Influenza virus vaccine (split virion, inactivated)

Sponsor

Sanofi Pasteur, a Sanofi Company